CorMedix Inc. (CRMD)

CorMedix Inc.'s stock price has experienced significant volatility in the past six months. The stock saw a substantial decline of 37.72% over this period. In early January 2026, shares plunged approximately 28% after the company issued a cautious full-year 2026 revenue outlook. Prior to this, in November 2025, the stock experienced a positive surge following a "blowout" third-quarter 2025 earnings report. The acquisition of Melinta Therapeutics LLC in August 2025 was a transformative event, diversifying the company's product portfolio and revenue streams.

The demand for CorMedix's lead product, DefenCath, does not exhibit historical seasonality. The company has observed a continuous increase in utilization and overall revenue growth for DefenCath as it has added new customers and cohorts.

CorMedix Inc. is a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases. Its lead product, DefenCath, is an antimicrobial catheter lock solution for reducing catheter-related bloodstream infections in hemodialysis patients. CorMedix commercially launched DefenCath in inpatient settings in April 2024 and in outpatient settings in July 2024. In August 2025, CorMedix acquired Melinta Therapeutics LLC, expanding its portfolio with anti-infective products. The company is also conducting clinical studies for DefenCath in adult Total Parenteral Nutrition (TPN) patients and pediatric hemodialysis populations.

CorMedix Inc. is headquartered in Berkeley Heights, New Jersey, United States. The company primarily focuses on developing and commercializing its therapeutic products within the United States and other key markets. Its "Drug Product" segment currently operates in a single geographic location, the United States.

CorMedix's brand reputation has been subject to mixed sentiment in the past year. Analyst ratings generally show a "Buy" consensus with an average price target of $17.86. However, the company's cautious 2026 revenue outlook has negatively impacted its reputation, leading to concerns among investors and a significant drop in stock price. Leadership changes and significant insider selling could be perceived negatively by the market.

CorMedix Inc. has a diverse ownership structure, with individual investors holding the largest share at 59%, and institutional ownership ranging from approximately 34% to 55.2%. Major institutional shareholders include BlackRock, Inc., Vanguard Group Inc, Marshall Wace, Llp, Deerfield Management Company, L.p. (series C), State Street Corp, Geode Capital Management, Llc, Citadel Advisors Llc, and Alyeska Investment Group, L.P. Gary A. Gelbfish is a significant individual shareholder, owning 3.48% of the company's shares. Company insiders have sold more shares than they have bought over the past three months.